Prime Medicine, Inc. (PRME) Stock Price & Analysis
Prime Medicine, Inc. (PRME) closed at USD 3.67 on Friday, October 23, 2026, down 1.61% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 3.67; the Oct 23, 2026 session ranged USD 3.38–3.7 on volume of 4,536,739 shares. Market capitalization is —, with a 52-week range of USD 2.67–5.55 (NGM). Source: Nexqual, retrieved October 23, 2026 at 23:36 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PRME.md
Key facts (PRME)
- Total return with dividends: 1Y -31.1% vs S&P 500 +13.4%; 5Y -76.7% vs S&P 500 +76.9%.
- Next earnings: 2026-11-06, EPS estimate USD -0.23, revenue estimate $1.1M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PRME)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0K | $0K | $0K | $3.0M | $4.6M | — |
| Operating income | -$84.5M | -$117M | -$205M | -$202M | -$208M | -$197M |
| Net income | -$165M | -$122M | -$198M | -$196M | -$201M | -$188M |
| EPS (diluted) | -$14.19 | -$4.19 | -$2.18 | -$1.65 | -$1.35 | — |
| Free cash flow | -$38.2M | -$148M | -$174M | -$130M | -$167M | -$157M |
| Operating margin | — | — | — | -6787.4% | -4498.1% | — |
| Net margin | — | — | — | -6566.6% | -4342.4% | — |
| Revenue growth | -100.0% | — | — | — | +55.3% | — |
| Cash + short-term investments | $254M | $294M | $122M | $190M | $178M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (PRME)
Analysts (PRME)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-25 | Chardan Capital | Maintained | Buy | $7 |
| 2026-08-25 | Chardan Capital | Maintained | Buy | $7 |
| 2026-08-19 | BMO Capital | Initiated | Outperform | $9 |
| 2026-08-10 | HC Wainwright & Co. | Reiterated | Buy | $8 |
| 2026-06-29 | HC Wainwright & Co. | Upgrade | Neutral → Buy | $8 |
Total return (dividends reinvested) (PRME)
| 1Y (from 2025-10-24) | 5Y (from 2022-10-17) | |
|---|---|---|
| Total return | -31.1% | -76.7% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -31.2% | -30.4% |
| Volatility (annualized) | 86.2% | 88.8% |
| Max drawdown | -49.3% (Oct 2025→May 2026) | -94.4% (Nov 2022→May 2025) |
PRME suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Beam Therapeutics Inc. (BEAM) | “•We may enter into collaborations with collaborators and strategic partners such as Beam Therapeutics Inc., or Beam, or other third parties for the research, development, delivery, manufacturing and commercialization of Prime Editing technology and certain of the product candidates we may develop.” |
| Partner | Broad Institute | “In September 2019, we entered into a license agreement with Broad Institute, or the Broad License Agreement, and in May 2020, February 2021, December 2022, September 2024, and September 2025 we entered into amendments to that Broad License Agreement.” |
| Partner | Myeloid Therapeutics | “In 2023, we terminated the Myeloid Collaboration Agreement.” |
| Partner | KMG Strategic Consulting | “In May 2025, pursuant to the Gottesdiener Separation Agreement and Gottesdiener Employment Agreement, we entered into a consulting agreement with KMG Strategic Consulting, LLC, or the KMG Consulting Agreement, a limited liability company managed by Dr. Gottesdiener, to provide for Dr. Gottesdiener's continued consulting services to us.” |
| Competitor | Moderna (MRNA) | “Other companies have announced intentions to enter the gene editing field, such as Moderna, Inc. and Pfizer Inc. Most recently, new epigenetic editing companies have emerged, such as Moonwalk Biosciences, Inc., nChroma Bio, Inc. and Tune Therapeutics, Inc. In addition, we face competition from companies utilizing gene therapy, oligonucleotides and cell therapy therapeutic approaches.” |
| Competitor | Pfizer (PFE) | “Other companies have announced intentions to enter the gene editing field, such as Moderna, Inc. and Pfizer Inc. Most recently, new epigenetic editing companies have emerged, such as Moonwalk Biosciences, Inc., nChroma Bio, Inc. and Tune Therapeutics, Inc. In addition, we face competition from companies utilizing gene therapy, oligonucleotides and cell therapy therapeutic approaches.” |
Quoted from the company's 10-K filed Mar 3, 2026.
PRME company outlook (results filed Aug 6, 2026)
- “Based on its current operating plans, Prime Medicine expects that its cash, cash equivalents and investments as of June 30, 2026 will be sufficient to fund its operating expenses and capital expenditure requirements into 2027.”
Quoted word-for-word from the SEC 8-K results press release.
PRME analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.23 | $-0.23 | +2.8% | $1.1M | 13 |
| Next quarter (ends Dec 2026) | $-0.22 | $-0.23 | -4.6% | $6.5M | 13 |
| Current fiscal year (ends Dec 2026) | $-0.94 | $-0.99 | -4.1% | $8.8M | 14 |
| Next fiscal year (ends Dec 2027) | $-0.89 | $-0.84 | +5.5% | $10.6M | 12 |
PRME options: expected move
Options price a move of about ±27.5% (±$1.00) by Nov 20, 2026, which includes earnings on Nov 6, 2026. Over the last 8 reports the stock moved ±7.3% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 104.9% | ±27.5% |
| Dec 18, 2026 | 56 | 110.7% | ±37.1% |
| Jan 15, 2027 | 84 | 104.9% | ±39.8% |
| Apr 16, 2027 | 175 | 108.5% | ±57.7% |
30-day implied volatility 109.4% vs 109.4% realized over the last 30 trading days. Put/call ratio (volume) 1.63. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 23:36 UTC)
| Price | USD 3.67 |
|---|---|
| Change | ▼ 1.61% (down) |
| Previous Close | USD 3.67 |
| Open | USD 3.67 |
| Day Range | USD 3.38 – 3.7 |
| 52-Week Range | USD 2.67 – 5.55 |
| Volume | 4,536,739 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (PRME)
Nexqual's technical model rates PRME "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 23:36 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 52.22 (neutral) |
| vs SMA50 | Above (USD 3.39) |
| MACD | 0.13 (positive) |
Earnings (PRME)
| Next Earnings Date | 2026-11-06 |
|---|---|
| EPS Estimate | USD -0.23 |
| Revenue Estimate | $1.10M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.24 vs est -0.26 ▲ beat |
| 2026-03-31 | USD -0.28 vs est -0.25 ▼ miss |
| 2025-12-31 | USD -0.24 vs est -0.26 ▲ beat |
| 2025-09-30 | USD -0.32 vs est -0.25 ▼ miss |
Source: Nexqual, October 23, 2026 at 23:36 UTC.
Financials & Fundamentals (PRME)
| Total Revenue | $4.07M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +3.50% |
| Gross Margin | +0.00% |
| Operating Margin | -3750.87% |
| Profit Margin | +0.00% |
| ROE | -373.29% |
| Debt / Equity | 2.83 |
| Current Ratio | 3.06 |
| Total Cash | $95.07M |
| Total Debt | $112.48M |
Source: Nexqual, October 23, 2026 at 23:36 UTC.
Ownership (PRME)
| Insider Ownership | +20.30% |
|---|---|
| Institutional Ownership | +70.98% |
| Shares Outstanding | 181.38M |
| Float | 112.25M |
| Short % of Float | +22.64% |
Source: Nexqual, October 23, 2026 at 23:36 UTC.
From Prime Medicine, Inc.'s Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- We expect our focus on liver-directed in vivo editing, combined with the modularity of our platform, will allow us to build a pipeline with breadth and depth while maintaining operational efficiency and disciplined capital deployment.
- Our approach is grounded in Prime Editing, a next-generation gene editing technology that enables targeted modifications to genomic DNA without introducing double-stranded breaks.
- We believe Prime Editing represents the most versatile and precise method for rewriting, replacing, or repairing DNA sequences and may allow us to address a broad spectrum of diseases with an improved safety and specificity profile relative to earlier editing technologies.
- We have developed a suite of Prime Editors optimized for different cell types and genomic contexts.
Partnerships
- We received a $55.0 million upfront payment under the BMS Collaboration Agreement and a $55.0 million equity investment under a Securities Purchase Agreement with BMS.
- In January 2024, we entered into an agreement with CFF, or the 2024 CFF Agreement, under which CFF agreed to provide up to $15.0 million, payable in multiple tranches, to support the development of Prime Editors for the treatment of CF.
Legal & Regulatory Risks (Item 1A, quoted)
- The FDA, the EMA and the NIH have demonstrated caution in their regulation of gene therapy treatments, and ethical and legal concerns about gene therapy and genetic testing may result in additional regulations or restrictions on the development and commercialization of any product candidates we may develop, which may be difficult to predict.
- We may not be able to obtain orphan drug designation or exclusivity for our current or future product candidates, and even if we do, that designation may not provide an expedited development or regulatory review or approval process and any orphan drug exclusivity we may receive for approved products may not prevent the FDA or the European Commission from approving other competing products.
- We may seek designation for our Prime Editing platform technology as a designated platform technology, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process.
- Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 303.53 | ▼ 1.39% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 89.27 | ▼ 1.79% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.09 | ▼ 0.35% |
| PRAX | Praxis Precision Medicines, Inc | USD 252.96 | ▼ 2.3% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 42.93 | ▼ 2.23% |
| AXSM | Axsome Therapeutics, Inc. | USD 145.04 | ▼ 7.07% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 23:36 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt